We are excited to announce a new product is joining our suite of cannabis extracts: Tilray 2:100, our new high-CBD cannabis oil.
Tilray 2:100 contains a target concentration of 2 mg/mL THC and 100 mg/mL CBD, and a target content of 80 mg THC and 4,000 mg CBD per bottle – the highest CBD concentration available in the Canadian medical cannabis marketplace today.
This high-CBD extract has the same target concentration of THC and CBD as the study drug used in recent trial on pediatric epilepsy conducted at the Hospital for Sick Children (SickKids) in Toronto. That trial, which is proudly supported by Tilray, studies how children with Dravet Syndrome, a rare and debilitating form of epilepsy, respond to adjunct therapy with a high-CBD medical cannabis extract.
Patients with epilepsy will receive priority access to this specialty product with an approved referral from an epileptologist, neurologist or pediatrician.
For patients with other conditions who are interested in high-CBD medical cannabis extracts, we encourage you to look at our 1:25 CBD oil, which contains 1 mg/mL THC and 25 mg/mL CBD, and 5:20 CBD oil, which contains 5 mg/mL THC and 20 mg/mL CBD. These two products may be a suitable and affordable option for the majority of our Tilray patients who prefer CBD.
Tilray is focused on Improving Lives Through Medical Cannabis and the addition of 2:100 cannabis oil is an important step to support this goal.
For more information on Tilray’s medical cannabis products, please call Patient Services toll-free at 1-844-TILRAY1 or email email@example.com.